Title of Invention: Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators Abstract: This invention is directed to a cannabinoid modulator compound of formula (I): or a form thereof, and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease. Detailed Description: Part general_description_paragraphs: Part FIELD OF THE INVENTION: This invention is directed to substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid (CB) modulator compounds and methods for use in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease. Part BACKGROUND OF THE INVENTION: Before the discovery of the cannabinoid CB1 and CB2 receptors, the term cannabinoid was used to describe the biologically active components of cannabis sativa, the most abundant of which are delta-9-tetrahydrocannabinol (THC) and cannabidiol. THC is a moderately potent partial agonist of the CB1 and CB2 receptors and is considered the “classical cannabinoid,” a term now used to refer to other analogues and derivatives that are structurally related to the tricyclic dibenzopyran THC core. The term “nonclassical cannabinoid” refers to cannabinoid agonists structurally related to cannabidiol. Pharmacological investigations have concentrated on selective CB receptor modulators of the pyrazole structural class, which include SR 141716A (the monohydrochloride salt of SR 141716) and SR 144528. Pyrazole cannabinoid modulators are one among the many different structural classes which have aided the development of CB pharmacology, have helped to determine the biological effects mediated by the cannabinoid receptors, will lead to further refinement of current compounds and will be a source of new chemical classes in the future. Certain compounds (including SR 141716, SR 144528 and the like) that were originally classified as selective antagonists are now considered to act as “inverse agonists” rather than pure antagonists. Inverse agonists have the ability to decrease the constitutive level of receptor activation in the absence of an agonist instead of only blocking the activation induced by agonist binding at the receptor. The constitutive activity of CB receptors has important implications since there is a level of continuous signaling by both CB1 and CB2 even in the absence of an agonist. For example, SR 141716A increases CB1 protein levels and sensitizes cells toward agonist action, thus indicating that inverse agonists may be another class of ligands used to modulate the endocannabinoid system and the downstream signaling pathways activated by CB receptors. Advances in the synthesis of CB and cannabimimetic ligands have furthered the development of receptor pharmacology and provided evidence for the existence of additional cannabinoid receptor sub-types. However, there remains an ongoing need for the identification and development of CB1 or CB2 receptor cannabinoid modulators for the treatment of a variety of CB receptor modulated syndromes, disorders and diseases. Part SUMMARY OF THE INVENTION: The present invention is directed to a compound of formula (I): or a form thereof, useful as a cannabinoid receptor modulator, wherein R1a, R1b, R2 and R3 are as defined herein. The present invention is also directed to a method for use of a compound of formula (I) in treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease. The present invention is further directed to a method for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of formula (I). Part DETAILED DESCRIPTION OF THE INVENTION: This invention is directed to a compound having a structure according to formula (I): or a form thereof, wherein R1a is hydrogen or alkyl; R1b is selected from C3-12cycloalkyl, heterocyclyl, aryl, heteroaryl or alkyl, wherein alkyl is optionally substituted with carboxy, C3-12cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein each instance of C3-12cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally substituted with one, two, three or four substituents selected from alkyl, alkoxy, cyano, halogen, hydroxy, amino or alkylamino, and wherein heterocyclyl optionally has one nitrogen ring atom attached to the formula (I) nitrogen atom, wherein said nitrogen ring atom is optionally further substituted with alkyl to form a quaternary ammonium salt; alternatively, R1a and R1b are taken together with the nitrogen atom of attachment to form a ring selected from piperidinyl or piperazinyl; and, R2 and R3 are each selected from one or two alkyl, alkoxy, cyano or halogen substituents. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1a is hydrogen. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is selected from C3-12cycloalkyl, heterocyclyl, aryl or alkyl, wherein alkyl is optionally substituted with carboxy, C3-12cycloalkyl or aryl, wherein each instance of C3-12cycloalkyl or aryl is optionally substituted with one, two, three or four substituents selected from alkyl, alkoxy, cyano, halogen, hydroxy, amino or alkylamino. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is selected from C3-12cycloalkyl, heterocyclyl, aryl or alkyl, wherein alkyl is optionally substituted with C3-12cycloalkyl or aryl, wherein each instance of C3-12cycloalkyl is optionally substituted with one, two or three alkyl substituents, and wherein each instance of aryl is optionally substituted with an amino or alkylamino substituent. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is selected from cyclohexyl, bicyclo[2.2.1]heptyl, piperidinyl, morpholinyl, phenyl or alkyl, wherein alkyl is optionally substituted with carboxy, cyclohexyl or phenyl, wherein each instance of cyclohexyl or bicyclo[2.2.1]heptyl is optionally substituted with one, two or three methyl or ethyl substituents, and wherein each instance of phenyl is optionally substituted with an amino or alkylamino substituent. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is selected from C3-12cycloalkyl, heterocyclyl or alkyl, wherein alkyl is optionally substituted with C3-12cycloalkyl or aryl, wherein C3-12cycloalkyl is optionally substituted with three alkyl substituents. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is selected from bicyclo[2.2.1]heptyl, piperidinyl or alkyl, wherein alkyl is optionally substituted with cyclohexyl or phenyl, wherein bicyclo[2.2.1]heptyl is optionally substituted with three alkyl substituents. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1b is piperidinyl having one nitrogen ring atom attached to the formula (I) nitrogen atom, wherein said nitrogen ring atom is optionally further substituted with methyl to form a quaternary piperidinium salt. An example of the present invention is a compound of formula (I) or a form thereof, wherein R2 and R3 are one or two substituents selected from fluoro or chloro. An example of the present invention is a compound of formula (I) or a form thereof, wherein R2 is two substituents selected from fluoro or chloro. An example of the present invention is a compound of formula (I) or a form thereof, wherein R2 is two chloro substituents. An example of the present invention is a compound of formula (I) or a form thereof, wherein R3 is one chloro substituent. An example of the present invention is a compound of formula (I) or a form thereof, wherein R1a is hydrogen; R1b is selected from cyclohexyl, bicyclo [2.2.1]heptyl, piperidinyl, morpholinyl, phenyl or alkyl, wherein alkyl is optionally substituted with carboxy, cyclohexyl or phenyl, wherein each instance of cyclohexyl or bicyclo[2.2.1]heptyl is optionally substituted with one, two or three methyl or ethyl substituents, and wherein each instance of phenyl is optionally substituted with an amino or alkylamino substituent, or R1b is piperidinyl having one nitrogen ring atom attached to the formula (I) nitrogen atom, wherein said nitrogen ring atom is optionally further substituted with methyl to form a quaternary piperidinium salt; R2 is two substituents selected from fluoro or chloro; and R3 is one chloro substituent. An example of the present invention is a compound of formula (I) or a form thereof wherein R1a is hydrogen and R1b, R2 and R3 are dependently selected from: Cpd R1b R2 R3 1 (1S)-1-cyclohexyl-ethyl 2,4-Cl2 4-Cl 2 (1S)-1-phenyl-ethyl 2,4-Cl2 4-Cl 3 (1R,2S,4R)-1,3,3-trimethyl- 2,4-Cl2 4-Cl bicyclo[2.2.1]hept-2-yl) 4 piperidin-1-yl 2,4-Cl2 4-Cl 5 morpholin-4-yl 2,4-Cl2 4-Cl 6 cyclohexyl 2,4-Cl2 4-Cl 7 2-methyl-cyclohexyl 2,4-Cl2 4-Cl 8 (1R)-1-cyclohexyl-ethyl 2,4-Cl2 4-Cl 9 cyclohexyl-methyl 2,4-Cl2 4-Cl 10 phenyl 2,4-Cl2 4-Cl 11 (1R)-1-phenyl-ethyl 2,4-Cl2 4-Cl 12 piperidin-1-yl 2,4-Cl2 3-Cl 13 morpholin-4-yl 2,4-Cl2 3-Cl 14 1-methyl-piperidinium 2,4-Cl2 4-Cl 15 (C-carboxy-C-phenyl)-methyl 2,4-Cl2 3-Cl 16 (1S)-1-cyclohexyl-ethyl 2,4-Cl2 3-Cl 17 (1S)-1-phenyl-ethyl 2,4-Cl2 3-Cl 18 (1R)-1-cyclohexyl-ethyl 2,4-Cl2 3-Cl 19 (1R)-1-phenyl-ethyl 2,4-Cl2 3-Cl 20 2-amino-phenyl 2,4-Cl2 3-Cl 21 (1S)-1-cyclohexyl-ethyl 2,4-F2 4-Cl 22 (1S)-1-phenyl-ethyl 2,4-F2 4-Cl 23 (1R)-1-phenyl-ethyl 2,4-F2 4-Cl 24 (1R)-1-cyclohexyl-ethyl 2,4-F2 4-Cl 25 piperidin-1-yl 2,4-F2 4-Cl 26 morpholin-4-yl 2,4-F2 4-Cl 27 methyl 2,4-Cl2 4-Cl 28 R-but-2-yl 2,4-Cl2 4-Cl 29 S-but-2-yl 2,4-Cl2 4-Cl An example of the present invention is a compound or a form thereof selected from the group consisting of: An example of the present invention includes a representative compound or a form thereof selected from the group consisting of: Cpd Name 1 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl- ethyl]-amide, 2 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 3 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R,2S,4R)-1,3,3-trimethyl- bicyclo[2.2.1]hept-2-yl]-amide, 4 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 5 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide, 6 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid cyclohexylamide, 7 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1- (2,4-dichloro-phenyl)-4-methyl-1H-pyrazole- 3-carboxylic acid (2-methyl-cyclohexyl)-amide, 8 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl- ethyl]-amide, 9 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid cyclohexylmethyl-amide, 10 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid phenylamide, 11 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl- ethyl]-amide, 12 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 13 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide, 14 1-{[5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro- phenyl)-4-methyl-1H-pyrazole-3-carbonyl]-amino}-1- methyl-piperidinium, 15 {[5-[2-(3-chloro-phenyl)-1-methyl-vinyl]- 1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carbonyl]-amino}-phenyl-acetic acid, 16 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl- ethyl]-amide, 17 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 18 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl- ethyl]-amide, 19 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl- ethyl]-amide, 20 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid (2-amino-phenyl)-amide, 21 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl- ethyl]-amide, 22 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl- ethyl]-amide, 23 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]- amide, 24 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]- amide, 25 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 26 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide, 27 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid methylamide, 28 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(R)-sec-butyl]-amide, and 29 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(S)-sec-butyl]-amide. Another example of the present invention includes a compound or a form thereof selected from the group consisting of: Cpd Name 1 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]- amide, 2 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 3 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R,2S,4R)-1,3,3-trimethyl- bicyclo[2.2.1]hept-2-yl]-amide, 4 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 5 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide, 6 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid cyclohexylamide, 7 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid (2-methyl-cyclohexyl)- amide, 8 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]- amide, 9 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid cyclohexylmethyl-amide, 10 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid phenylamide, 11 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]- amide, 12 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 13 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid morpholin-4-ylamide, 16 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]- amide, 17 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 18 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]- amide, 19 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]- amide, 21 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-cyclohexyl-ethyl]- amide, 23 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-phenyl-ethyl]- amide, 24 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-difluoro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl-ethyl]- amide, 28 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(R)-sec-butyl]-amide, and 29 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(S)-sec-butyl]-amide. A further example of the present invention includes a compound or a form thereof selected from the group consisting of: Cpd Name 1 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1- cyclohexyl-ethyl]-amide, 2 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1S)-1-phenyl-ethyl]-amide, 3 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R,2S,4R)-1,3,3-trimethyl- bicyclo[2.2.1]hept-2-yl]-amide, 4 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide, 18 5-[2-(3-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(1R)-1-cyclohexyl- ethyl]-amide, and 28 5-[2-(4-chloro-phenyl)-1-methyl-vinyl]-1-(2,4-dichloro-phenyl)-4- methyl-1H-pyrazole-3-carboxylic acid [(R)-sec-butyl]-amide. Definitions As used herein, the following terms are intended to have the following definitions. The definitions herein may specify that the chemical term has an indicated formula. The particular formula provided is not intended to limit the scope of the invention, but is provided as an illustration of the term. The scope of the per se definition of the term is intended to include the plurality of variations expected to be included by one of ordinary skill in the art. The term “alkyl” means a saturated branched or straight chain monovalent hydrocarbon radical of up to 10 carbon atoms. Alkyl typically includes, but is not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, pentyl, hexyl, heptyl and the like. When further substituted, substituent variables may be placed on any alkyl carbon atom. The term “alkenyl” means a partially unsaturated branched or straight chain monovalent hydrocarbon radical of up to 10 carbon atoms having at least one carbon-carbon double bond, whereby the double bond is derived by the removal of one hydrogen atom from each of two adjacent carbon atoms. Alkenyl typically includes, but is not limited to, ethenyl (vinyl), propenyl (allyl or 2-propenyl), butenyl and the like. When further substituted, substituent variables may be placed on any alkyl carbon atom. The term “alkoxy” means a radical of the formula: —O-alkyl. Alkoxy typically includes, but is not limited to, methoxy, ethoxy, propoxy, butoxy and the like. When further substituted, substituent variables may be placed on any alkoxy carbon atom. The term “C3-12 cycloalkyl” means a saturated or partially unsaturated hydrocarbon ring system radical or linking group. The term “C3-12 cycloalkyl” also includes a C3-8 cycloalkyl, C3-10 cycloalkyl, C5-8 cycloalkyl, C5-12 cycloalkyl or C9-12 cycloalkyl ring system radical and the like such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, indanyl, indenyl, 1,2,3,4-tetrahydro-naphthalenyl, 5,6,7,8-tetrahydro-naphthalenyl, 6,7,8,9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9,10-hexahydro-benzocyclooctenyl, fluorenyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, bicyclo[2.2.2]octyl, bicyclo[3.1.1]heptyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octenyl, bicyclo[3.2.1]octenyl, adamantanyl, octahydro-4,7-methano-1H-indenyl, octahydro-2,5-methano-pentalenyl (also referred to as hexahydro-2,5-methano-pentalenyl) and the like. When further substituted, substituent variables may be placed on any ring carbon atom. The term “heterocyclyl” means a saturated or partially unsaturated ring system radical, wherein at least one ring carbon atom has been replaced with one or more heteroatoms independently selected from N, O, S, S(O) or SO2. A heterocyclyl ring system further includes a ring system having 1, 2, 3, or 4 carbon atom members replaced by a nitrogen atom. Alternatively, a ring may have 0, 1, 2, or 3 nitrogen atom members and 1 oxygen or sulfur atom member. Alternatively, up to two adjacent ring members may be heteroatoms, wherein one heteroatom is nitrogen and the other heteroatom is selected from N, S, or O. Heterocyclyl typically includes, but is not limited to, furyl, thienyl, 2H-pyrrole, 2-pyrrolinyl, 3-pyrrolinyl, pyrrolidinyl, pyrrolyl, 1,3-dioxolanyl, oxazolyl, thiazolyl, imidazolyl, 2-imidazolinyl (also referred to as 4,5-dihydro-1H-imidazolyl), imidazolidinyl, 2-pyrazolinyl, pyrazolidinyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, tetrazolyl, tetrazolidinyl, 2H-pyran, 4H-pyran, pyridinyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperazinyl, azetidinyl, azepanyl, indolizinyl, indolyl, isoindolyl, 3H-indolyl, indolinyl (also referred to as 2,3-dihydro-indolyl), benzo[b]furyl, benzo[b]thienyl, 1H-indazolyl, benzimidazolyl, benzthiazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl, quinuclidinyl, hexahydro-1,4-diazepinyl, 1,3-benzodioxolyl (also known as 1,3-methylenedioxyphenyl or benzo[1,3]dioxolyl), 2,3-dihydro-1,4-benzodioxinyl (also known as 1,4-ethylenedioxyphenyl), tetrahydro-furanyl, benzo-dihydro-furanyl, tetrahydro-pyranyl, benzo-tetrahydro-pyranyl, tetrahydro-thienyl, benzo-dihydro-thienyl, 5,6,7,8-tetrahydro-4H-cyclohepta(b)thienyl, 5,6,7-trihydro-4H-cyclohexa(b)thienyl, 5,6-dihydro-4H-cyclopenta(b)thienyl, tetrahydro-pyridazinyl, hexahydro-1,4-diazepinyl, hexahydro-1,4-oxazepanyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydro-benzofuranyl 2-aza-bicyclo[2.2.1]heptyl, 1-aza-bicyclo[2.2.2]octyl, 8-aza-bicyclo[3.2.1]octyl, 7-oxa-bicyclo[2.2.1]heptyl and the like. The term “aryl” means a monovalent, unsaturated aromatic hydrocarbon ring system radical. Aryl ring systems include phenyl, naphthalenyl, azulenyl, anthracenyl and the like. The term “heteroaryl” means a monovalent, unsaturated aromatic hydrocarbon ring system radical, wherein at least one ring carbon atom has been replaced with one or more heteroatoms independently selected from N, O, S, S(O) or SO2, as defined in heterocyclyl above. Heteroaryl ring systems include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl, azaindolyl, isoindolyl, benzo[b]furanyl, benzo[b]thienyl, indazolyl, azaindazolyl, benzoimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, 4H-quinolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalzinyl, quinazolinyl, quinoxalinyl, 1,8-naphthyridinyl, pteridinyl and the like. The term “amino” means a radical of the formula: —NH2. The term “alkylamino” means a radical of the formula: —NH-alkyl or N(alkyl)2. The term “carboxy” means a radical of the formula: —C(O)—OH. The term “halogen” means the group chloro, bromo, fluoro or iodo. The term “substituted” means one or more hydrogen atoms on a core molecule have been replaced with one or more radicals or linking groups, wherein the linking group, by definition is also further substituted. The ability of a particular radical or linking group to replace a hydrogen atom is optimally expected by one skilled to art to result in a chemically stable molecule. The term “dependently selected” means that the structure variables are specified in an indicated combination. In general, IUPAC nomenclature rules are used throughout this disclosure. Pharmaceutical Forms The term “form” or “isolated form”, in any context herein, means that certain compounds of the present invention may exist in various isolated states such as, without limitation, a salt, stereoisomer, crystalline, polymorph, amorphous, solvate, hydrate, ester, prodrug or metabolite form. The present invention encompasses all such compound forms and mixtures thereof, including active compounds in the form of essentially pure enantiomers, racemic mixtures, pure geometric isomers (such as cis and trans stereoisomers), mixtures of geometric isomers and tautomers. The compounds of the present invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the “pharmaceutically acceptable salts” of the compounds of this invention refer to non-toxic acidic/anionic or basic/cationic salt forms. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore when the compounds of the present invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include the following: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, camsylate (or camphosulfonate), carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, fumarate, gluconate, glutamate, hydrabamine, hydrobromine, hydrochloride, iodide, isothionate, lactate, malate, maleate, mandelate, mesylate, nitrate, oleate, pamoate, palmitate, phosphate/diphosphate, salicylate, stearate, sulfate, succinate, tartrate, tosylate. The present invention includes within its scope prodrugs and metabolites of the compounds of this invention. In general, such prodrugs and metabolites will be functional derivatives of the compounds that are readily convertible in vivo into an active compound. Thus, in the methods of treatment of the present invention, the term “administering” shall encompass the means for treating, ameliorating or preventing a syndrome, disorder or disease described herein with a compound specifically disclosed or a compound, or prodrug or metabolite thereof, which would obviously be included within the scope of the invention albeit not specifically disclosed for certain of the instant compounds. The term “prodrug” means a pharmaceutically acceptable form of a functional derivative of a compound of the invention (or a salt thereof), wherein the prodrug may be: 1) a relatively active precursor which converts in vivo to an active prodrug component; 2) a relatively inactive precursor which converts in vivo to an active prodrug component; or 3) a relatively less active component of the compound that contributes to therapeutic biological activity after becoming available in vivo (i.e., as a metabolite). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described in, for example, “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985. The term “metabolite” means a pharmaceutically acceptable form of a metabolic derivative of a compound of the invention(or a salt thereof), wherein the derivative is a relatively less active component of the compound that contributes to therapeutic biological activity after becoming available in vivo. The present invention contemplates compounds of various isomers and mixtures thereof. The term “isomer” refers to compounds that have the same composition and molecular weight but differ in a physical or chemical property, or both. Such substances have the same number and kind of atoms but differ in structure. The structural difference may be in constitution (geometric isomers) or in an ability to rotate the plane of polarized light (stereoisomers). The term “stereoisomer” refers to isomers of identical constitution that differ in the arrangement of their atoms in space. Enantiomers and diastereomers are stereoisomers wherein an asymmetrically substituted carbon atom acts as a chiral center. The term “chiral” refers to a molecule that is not superposable on its mirror image, implying the absence of an axis and a plane or center of symmetry. The term “enantiomer” refers to one of a pair of molecular species that are mirror images of each other and are not superposable. The term “diastereomer” refers to stereoisomers that are not related as mirror images. The symbols “R” and “S” represent the configuration of substituents around a chiral carbon atom(s). The symbols “R*” and “S*” denote the relative configurations of substituents around a chiral carbon atom(s). . The term “racemate” or “racemic mixture” refers to a compound of equimolar quantities of two enantiomeric species, wherein the compound is devoid of optical activity. The term “optical activity” refers to the degree to which a chiral molecule or nonracemic mixture of chiral molecules rotates the plane of polarized light. The term “geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a bridged bicyclic system. Substituent atoms (other than hydrogen) on each side of a carbon-carbon double bond may be in an E or Z configuration according to the Cahn-Ingold-Prelog system sequence rules that rank the two substituent groups at each carbon atom. In the “E” configuration, the two higher ranking substituents are on opposite sides in relationship to the carbon-carbon double bond. In the “Z” configuration, the two higher ranking substituents are oriented on the same side in relationship to the carbon-carbon double bond. The isomeric descriptors (“R,” “S” “E,” and “Z”) indicate atom configurations relative to a core molecule and are intended to be used as defined in the literature. The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include combining the free base (or free acid) of each isomer of an isomeric pair using an optically active acid (or base) to form an optically active salt (followed by fractional crystallization and regeneration of the free base), forming an ester or amide of each of the isomers of an isomeric pair by reaction with an appropriate chiral auxiliary (followed by fractional crystallization or chromatographic separation and removal of the chiral auxiliary), or separating an isomeric mixture of either an intermediate or a final product using various well known chromatographic methods. Furthermore, compounds of the present invention may have one or more polymorph or amorphous crystalline forms and as such are intended to be included in the scope of the invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents (e.g., organic esters such as ethanolate and the like), and such are also intended to be encompassed within the scope of this invention. During any of the processes for preparation of the compounds of the present invention, protection of sensitive or reactive groups on any of the molecules concerned may be necessary or desirable, or both. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known in the art. Therapeutic Use CB1 and CB2 cannabinoid receptors belong to the G-protein-coupled receptor (GCPR) family, a receptor super-family with a distinctive pattern of seven transmembrane domains, which inhibits N-type calcium channels and/or adenylate cyclase to inhibit Q-type calcium channels. CB1 receptors are present in the CNS, predominately expressed in brain regions associated with memory and movement such as the hippocampus (memory storage), cerebellum (coordination of motor function, posture and balance), basal ganglia (movement control), hypothalamus (thermal regulation, neuroendocrine release, appetite), spinal cord (nociception), cerebral cortex (emesis) and periphery regions such as lymphoid organs (cell mediated and innate immunity), vascular smooth muscle cells (blood pressure), gastrointestinal tract (innate antiinflammatory in the tract and in the esophagus, duodenum, jejunum, ileum and colon, controlling esophageal and gastrointestinal motility), lung smooth muscle cells (bronchodilation), eye ciliary body (intraocular pressure). CB2 receptors appear to be primarily expressed peripherally in lymphoid tissue (cell mediated and innate immunity), peripheral nerve terminals (peripheral nervous system), spleen immune cells (immune system modulation) and retina (intraocular pressure). CB2 mRNA is found in the CNS in cerebellar granule cells (coordinating motor function). Pharmacological and physiological evidence also suggests that there may be other cannabinoid receptor subtypes that have yet to be cloned and characterized. Where activation or inhibition of a CB receptor appears to mediate various syndromes, disorders or diseases, potential areas of clinical application include, but are not limited to, controlling appetite, regulating metabolism, diabetes, reducing glaucoma-associated intraocular pressure, treating social and mood disorders, treating seizure-related disorders, treating substance abuse disorders, enhancing learning, cognition and memory, controlling organ contraction and muscle spasm, treating bowel disorders, treating respiratory disorders, treating locomotor activity or movement disorders, treating immune and inflammation disorders, regulating cell growth, use in pain management, use as a neuroprotective agent and the like or any combination thereof. Thus, cannabinoid receptor modulators, including the compounds of the formula (I) of the present invention, are useful for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease including, but not limited to, controlling appetite, regulating metabolism, diabetes, glaucoma-associated intraocular pressure, pain, social and mood disorders, seizure-related disorders, substance abuse disorders, learning, cognition disorders, memory disorders, bowel disorders, respiratory disorders, locomotor activity disorders, movement disorders, immune disorders or inflammation disorders, controlling organ contraction and muscle spasm, enhancing learning, enhancing cognition, enhancing memory, regulating cell growth, providing neuroprotection and the like or any combination thereof. The present invention is directed to a method for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of formula (I) or form thereof. The present invention is directed to a method for treating, ameliorating or preventing a cannabinoid receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject a combination product comprising an effective amount of a compound of formula (I) and a therapeutic agent. Therapeutic agents contemplated for use in a combination product of the present invention include an anticonvulsant or a contraceptive agent. The anticonvulsant agents include, and are not limited to, topiramate, analogs of topiramate, carbamazepine, valproic acid, lamotrigine, gabapentin, phenytoin and the like and mixtures or pharmaceutically acceptable salts thereof The contraceptive agents include, and are not limited to, such as progestin-only contraceptives and contraceptives that include both a progestin component and an estrogen component. The invention further includes a pharmaceutical composition wherein the contraceptive is an oral contraceptive, and wherein the contraceptive optionally includes a folic acid component. The invention also includes a method of contraception in a subject comprising the step of administering to the subject a composition, wherein the composition comprises a contraceptive and a CB1 receptor inverse-agonist or antagonist compound of formula (I), wherein the composition either reduces the urge to smoke in the subject or assists the subject in losing weight, or both. The present invention includes cannabinoid receptor modulators useful for treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease. The usefulness of a compound of the present invention or composition thereof as a CB modulator can be determined according to the methods disclosed herein. The scope of such use includes treating, ameliorating or preventing a plurality of CB receptor mediated syndromes, disorders or diseases. The present invention is also directed to a method for treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease in a subject in need thereof wherein the syndrome, disorder or disease is related to appetite, metabolism, diabetes, glaucoma-associated intraocular pressure, social and mood disorders, seizures, substance abuse, learning, cognition or memory, organ contraction or muscle spasm, bowel disorders, respiratory disorders, locomotor activity or movement disorders, immune and inflammation disorders, unregulated cell growth, pain management, neuroprotection and the like. A compound of formula (I) for use as a CB receptor modulator includes a compound having a mean inhibition constant (IC50) for CB receptor binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB1 agonist IC50 for CB1 agonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB1 antagonist IC50 for CB1 antagonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB1 inverse-agonist IC50 for CB1 inverse-agonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB2 agonist IC50 for CB2 agonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB2 antagonist IC50 for CB2 antagonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. A compound of formula (I) for use as a CB receptor modulator of the invention includes a compound having a CB2 inverse-agonist IC50 for CB2 inverse-agonist binding activity of between about 50 μM to about 0.01 nM; between about 25 μM to about 0.01 nM; between about 15 μM to about 0.01 nM; between about 10 μM to about 0.01 nM; between about 1 μM to about 0.01 nM; between about 800 nM to about 0.01 nM; between about 200 nM to about 0.01 nM; between about 100 nM to about 0.01 nM; between about 80 nM to about 0.01 nM; between about 20 nM to about 0.01 nM; between about 10 nM to about 0.1 nM; or about 0.1 nM. The term “cannabinoid receptor” refers to any one of the known or heretofore unknown subtypes of the class of cannabinoid receptors that may be bound by a cannabinoid modulator compound of the present invention; in particular, a cannabinoid receptor selected from the group consisting of a CB1 receptor and a CB2 receptor. The term “modulator” further refers to the use of a compound of the invention as a CB receptor agonist, antagonist or inverse-agonist. The present invention includes a method for treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the present invention or composition thereof, wherein the cannabinoid receptor is a CB1 or CB2 receptor; and, the compound is an agonist, antagonist or inverse-agonist of the receptor. The present invention includes a method for treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a compound of the present invention in a combination product with a therapeutic agent such as an anticonvulsant or contraceptive agent or composition thereof, wherein the cannabinoid receptor is a CB1 or CB2 receptor; and, the compound is an agonist, antagonist or inverse-agonist of the receptor. It should be understood that contraceptive agents suitable for use in a combination product are not limited to oral contraceptives, but also include other commonly available contraceptives such as those that are administered transdermally, by injection or via implant. Except as further specified, “combination product” means a pharmaceutical composition comprising a compound of formula (I) in combination with one or more therapeutic agents. The dosages of the compound of formula (I) and the one or more therapeutic agents are adjusted when combined to achieve an effective amount. The term “subject” as used herein, refers to a patient, which may be an animal, or a mammal or a human, which has been the object of treatment, observation or experiment and is at risk of (or susceptible to) developing a CB receptor mediated syndrome, disorder or disease. The term “administering” is to be interpreted in accordance with the methods of the present invention. Such methods include therapeutically or prophylactically administering an effective amount of a composition or medicament of the present invention at different times during the course of a therapy or concurrently as a product in a combination form. The term “medicament” refers to the use of a compound of formula (I) in the manufacture of a product for treating, ameliorating or preventing a CB receptor mediated syndrome, disorder or disease. Prophylactic administration can occur prior to the manifestation of symptoms characteristic of a CB receptor mediated syndrome, disorder or disease such that the syndrome, disorder or disease is treated, ameliorated, prevented or otherwise delayed in its progression. The methods of the present invention are further to be understood as embracing all therapeutic or prophylactic treatment regimens used by those skilled in the art. The term “effective amount” refers to that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, that is being sought by a researcher, veterinarian, medical doctor, or other clinician, which includes alleviation of the symptoms of the syndrome, disorder or disease being treated. The effective amount of an instant compound of the invention is from about 0.001 mg/kg/day to about 300 mg/kg/day. Wherein the present invention is directed to the administration of a combination of a compound of formula (I) and an anticonvulsant or contraceptive agent, the term “effective amount” means that amount of the combination of agents taken together so that the combined effect elicits the desired biological or medicinal response. As those skilled in the art will appreciate, the effective amounts of the components comprising the combination product may be independently optimized and combined to achieve a synergistic result whereby the pathology is reduced more than it would be if the components of the combination product were used alone. For example, the effective amount of a combination product comprising administration of a compound of formula (I) and topiramate would be the amount of the compound of formula (I) and the amount of topiramate that when taken together or sequentially have a combined effect that is effective. Further, it will be recognized by one skilled in the art that in the case of combination product with an effective amount, as in the example above, the amount of either or both the compound of formula (I) or the anticonvulsant (e.g., topiramate) individually may or may not be effective. Wherein the present invention is directed to the administration of a combination product, the instant compound and the anticonvulsant or contraceptive agent may be co-administered by any suitable means, simultaneously, sequentially or in a single pharmaceutical composition. Where the instant compound(s) and the anticonvulsant or contraceptive agent components are administered separately, the number of dosages of each compound(s) given per day, may not necessarily be the same, e.g. where one compound may have a greater duration of activity, and will therefore, be administered less frequently. The compound(s) of formula (I) and the anticonvulsant(s) or contraceptive agent(s) may be administered via the same or different routes of administration. The compound(s) of formula (I) and the anticonvulsant(s) or contraceptive agent(s) may be administered via the same or different routes of administration. Suitable examples of methods of administration are orally, intravenous (iv), intramuscular (im), and subcutaneous (sc). Compounds may also be administrated directly to the nervous system including, but not limited to the intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal or peri-spinal routes and the like or any combination thereof, or by delivery via intracranial or intravertebral needles and/or catheters with or without pump devices and the like or any combination thereof. The compound(s) of formula (I) and the anticonvulsant(s) or contraceptive agent(s) may be administered according to simultaneous or alternating regimens, at the same or different times during the course of the therapy, concurrently in divided or single forms. Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease condition. In addition, factors associated with the particular patient being treated, including patient's sex, age, weight, diet, time of administration and concomitant diseases, will result in the need to adjust dosages. The term “CB receptor mediated syndrome, disorder, or disease” refers to syndromes, disorders or diseases associated with a biological response mediated by a CB receptor such that there is discomfort or decreased life expectancy to the organism. CB receptor mediated syndromes, disorders or diseases can occur in both animals and humans and include appetite, metabolism, diabetes, obesity, glaucoma-associated intraocular pressure, social, mood, seizure, substance abuse, learning, cognition, memory, organ contraction, muscle spasm, bowel, respiratory, locomotor activity, movement, immune, inflammation, cell growth, pain or neurodegenerative related syndromes, disorders or diseases. Appetite related syndromes, disorders or diseases include obesity, overweight condition, anorexia, bulimia, cachexia, dysregulated appetite and the like. Obesity related syndromes, disorders or diseases include obesity as a result of genetics, diet, food intake volume, metabolic syndrome, disorder or disease, hypothalmic disorder or disease, age, reduced activity, abnormal adipose mass distribution, abnormal adipose compartment distribution and the like. Metabolism related syndromes, disorders or diseases include metabolic syndrome, dyslipidemia, elevated blood pressure, diabetes, insulin sensitivity or resistance, hyperinsulinemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, atherosclerosis, hepatomegaly, steatosis, abnormal alanine aminotransferase levels, inflammation, atherosclerosis and the like. Diabetes related syndromes, disorders or diseases include glucose dysregulation, insulin resistance, glucose intolerance, hyperinsulinemia, dyslipidemia, hypertension, obesity and the like. Type II diabetes mellitus (non-insulin-dependent diabetes mellitus) is a metabolic disorder (i.e., a metabolism related syndrome, disorder or disease) in which glucose dysregulation and insulin resistance results in chronic, long-term medical complications for both adolescents and adults affecting the eyes, kidneys, nerves and blood vessels and can lead to blindness, end-stage renal disease, myocardial infarction or limb amputation and the like. Glucose dysregulation includes the inability to make sufficient insulin (abnormal insulin secretion) and the inability to effectively use insulin (resistance to insulin action in target organs and tissues). Individuals suffering from Type II diabetes mellitus have a relative insulin deficiency. That is, in such individuals, plasma insulin levels are normal to high in absolute terms, although they are lower than predicted for the level of plasma glucose that is present. Type II diabetes mellitus is characterized by the following clinical signs or symptoms: persistently elevated plasma glucose concentration or hyperglycemia; polyuria; polydipsia and/or polyphagia; chronic microvascular complications such as retinopathy, nephropathy and neuropathy; and macrovascular complications such as hyperlipidemia and hypertension. These micro-and macro-vascular complications can lead to blindness, end-stage renal disease, limb amputation and myocardial infarction. Insulin Resistance Syndrome (IRS) (also referred to as Syndrome X, Metabolic Syndrome or Metabolic Syndrome X) is a disorder that presents risk factors for the development of Type II diabetes and cardiovascular disease including glucose intolerance, hyperinsulinemia, insulin resistance, dyslipidemia (e.g. high triglycerides, low HDL-cholesterol and the like), hypertension and obesity. Social or mood related syndromes, disorders or diseases include depression, anxiety, psychosis, social affective disorders or cognitive disorders and the like. Substance abuse related syndromes, disorders or diseases include drug abuse, drug withdrawal, alcohol abuse, alcohol withdrawal, nicotine withdrawal, cocaine abuse, cocaine withdrawal, heroin abuse, heroin withdrawal and the like. Learning, cognition or memory related syndromes, disorders or diseases include memory loss or impairment as a result of age, disease, side effects of medications (adverse events) and the like. Muscle spasm syndromes, disorders or diseases include multiple sclerosis, cerebral palsy and the like. Locomotor activity and movement syndromes, disorders or diseases include stroke, Parkinson's disease, multiple sclerosis, epilepsy and the like. Bowel related syndromes, disorders or diseases include bowel dysmotility associated disorders (either accompanied by pain, diarrhea or constipation or without), irritable bowel syndrome (and other forms of bowel dysmotility and the like), inflammatory bowel diseases (such as ulcerative colitis, Crohn's disease and the like) and celiac disease. Respiratory related syndromes, disorders or diseases include chronic pulmonary obstructive disorder, emphysema, asthma, bronchitis and the like. Immune or inflammation related syndromes, disorders or diseases include allergy, rheumatoid arthritis, dermatitis, autoimmune disease, immunodeficiency, chronic neuropathic pain and the like. Cell growth related syndromes, disorders or diseases include dysregulated mammalian cell proliferation, breast cancer cell proliferation, prostrate cancer cell proliferation and the like. Pain related syndromes, disorders or diseases include central and peripheral pathway mediated pain, bone and joint pain, migraine headache associated pain, cancer pain, menstrual cramps, labor pain and the like. Neurodegenerative related syndromes, disorders or diseases include Parkinson's Disease, multiple sclerosis, epilepsy, ischemia or secondary biochemical injury collateral to traumatic head or brain injury, brain inflammation, eye injury or stroke and the like. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid agonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid agonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid inverse-agonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid inverse-agonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid inverse-agonist compound of the present invention in a combination product with one or more contraceptives or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor antagonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid antagonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor antagonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a cannabinoid antagonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a cannabinoid receptor antagonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject a therapeutically or prophylactically effective amount of a cannabinoid antagonist compound of the present invention in a combination product with one or more contraceptives or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 agonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 agonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention in a combination product with one or more contraceptives or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated appetite related obesity related or metabolism related syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated appetite related obesity related or metabolism related syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention in a combination product with an anticonvulsant or composition thereof. The present invention includes a method for treating, ameliorating or preventing a CB1 receptor inverse-agonist mediated appetite related obesity related or metabolism related syndrome, disorder or disease in a subject in need thereof comprising the step of administering to the subject an effective amount of a CB1 inverse-agonist compound of the present invention in a combination product with one or more contraceptives or composition thereof. Appetite related syndromes, disorders or diseases include obesity, overweight condition, anorexia, bulimia, cachexia, dysregulated appetite and the like. Obesity related syndromes, disorders or diseases include obesity as a result of genetics, diet, food intake volume, metabolic syndrome, disorder
{'bibliographic_information': "{'country': 'US', 'doc-number': '12189230', 'kind': 'B2', 'date': '20080811', 'extension': '375', 'invention_title': 'Substituted 5-vinylphenyl-1-phenyl-pyrazole cannabinoid modulators'}", 'source_file': './grant/2011/ipg110517.xml', 'source_data': 'USPTO-Grant'}